Skip to content

Effect of Live combined Bifidobacterium, Lactobacillus and Enterococcus on clinical symptoms and gut microbiota and metabolites in Chinese children with Functional Constipation

Effect of Live combined Bifidobacterium, Lactobacillus and Enterococcus on clinical symptoms and gut microbiota and metabolites in Chinese children with Functional Constipation

Status
Recruiting
Phases
Phase 4
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR1900027956
Enrollment
Unknown
Registered
2019-12-07
Start date
2019-12-09
Completion date
Unknown
Last updated
2019-12-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Functional constipation

Interventions

Blank control group:Lifestyle guidance
Probiotics intervention group:Live Combined Bifidobacterium,Lactobacillus and Enterococcus

Sponsors

Ruijin Hospital, Shanghai Jiaotong University School of Medicine
Lead Sponsor

Eligibility

Sex/Gender
All
Age
4 Years to 14 Years

Inclusion criteria

Inclusion criteria: 1. Aged 4-14 years old; 2. Meet the Rome IV standards of the functional constipation for children and adolescents: Must include 2 or more of the following occurring at least once per week for a minimum of 1 month: 1) 2 or fewer defecations in the toilet per week; 2) At least 1 episode of fecal incontinence per week; 3) History of retentive posturing or excessive volitional stool retention; 4) History of painful or hard bowel movements; 5) Presence of a large fecal mass in the rectum; 6) History of large diameter stools that can obstruct the toilet; After appropriate evaluation, the symptoms cannot be fully explained by another medical condition.

Exclusion criteria

Exclusion criteria: 1. The study subjects have diseases that may cause changes in their bowel movements , such as history of gastrointestinal surgery, acute and chronic gastroenteritis, acute and chronic pancreatitis, hypothyroidism etc. 2. Allergic to Bifico powder/capsules. 3. Children with severe primary diseases such as cardiovascular, Central nervous system and haematological diseases; 4, Children with mental disorders and unclear discourse; 5, Children who have participated in other clinical trials within the previous 12 weeks; 6. According to the researcher's judgment, other conditions which may reduce the possibility of enrollment or complicate the enrollment, such as unstable living environment and inconvenient transportation.

Design outcomes

Primary

MeasureTime frame
Semi-quantitative score of abdominal symptoms;

Secondary

MeasureTime frame
16S rRNA Sequencing for stool microotganism;Targeted metabolomics analysis for detection of intestinal microbial metabolites;

Countries

China

Contacts

Public ContactChundi Xu

Ruijin Hospital, Shanghai Jiaotong University School of Medicine

chundixu55@163.com+86 13003231271

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026